These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1690776)

  • 1. Host-specific evasion of the alternative complement pathway by schistosomes correlates with the presence of a phospholipase C-sensitive surface molecule resembling human decay accelerating factor.
    Pearce EJ; Hall BF; Sher A
    J Immunol; 1990 Apr; 144(7):2751-6. PubMed ID: 1690776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of membrane components on regulation of alternative pathway activation by decay-accelerating factor.
    Mold C; Walter EI; Medof ME
    J Immunol; 1990 Dec; 145(11):3836-41. PubMed ID: 1700997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decay accelerating factor regulates complement activation on glomerular epithelial cells.
    Quigg RJ; Nicholson-Weller A; Cybulsky AV; Badalamenti J; Salant DJ
    J Immunol; 1989 Feb; 142(3):877-82. PubMed ID: 2464030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo.
    Moran P; Beasley H; Gorrell A; Martin E; Gribling P; Fuchs H; Gillett N; Burton LE; Caras IW
    J Immunol; 1992 Sep; 149(5):1736-43. PubMed ID: 1380537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of human decay-accelerating factor in the evasion of Schistosoma mansoni from the complement-mediated killing in vitro.
    Horta MF; Ramalho-Pinto FJ
    J Exp Med; 1991 Dec; 174(6):1399-406. PubMed ID: 1720809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of complement by Schistosoma mansoni schistosomula: killing of parasites by the alternative pathway and requirement of IgG for classical pathway activation.
    Santoro F; Lachmann PJ; Capron A; Capron M
    J Immunol; 1979 Oct; 123(4):1551-7. PubMed ID: 113459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Murine membrane inhibitor of complement which accelerates decay of human C3 convertase.
    Kameyoshi Y; Matsushita M; Okada H
    Immunology; 1989 Dec; 68(4):439-44. PubMed ID: 2481641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evasion of the alternative complement pathway by metacyclic trypomastigotes of Trypanosoma cruzi: dependence on the developmentally regulated synthesis of surface protein and N-linked carbohydrate.
    Sher A; Hieny S; Joiner K
    J Immunol; 1986 Nov; 137(9):2961-7. PubMed ID: 3531342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of complement activation on the homologous cell membrane of nucleated cells as well as erythrocytes.
    Okada H; Tanaka H; Okada N
    Eur J Immunol; 1983 Apr; 13(4):340-4. PubMed ID: 6221932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement activation induces the expression of decay-accelerating factor on human mesangial cells.
    Shibata T; Cosio FG; Birmingham DJ
    J Immunol; 1991 Dec; 147(11):3901-8. PubMed ID: 1719094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the alternative complement pathway by Leishmania promastigotes: parasite lysis and attachment to macrophages.
    Mosser DM; Edelson PJ
    J Immunol; 1984 Mar; 132(3):1501-5. PubMed ID: 6363545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decay-accelerating factor protects human trophoblast from complement-mediated attack.
    Cunningham DS; Tichenor JR
    Clin Immunol Immunopathol; 1995 Feb; 74(2):156-61. PubMed ID: 7530176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.
    Ito S; Tamura N; Fujita T
    Immunology; 1989 Dec; 68(4):449-52. PubMed ID: 2481642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decay-accelerating factor (DAF) shares a common carbohydrate determinant with the variant surface glycoprotein (VSG) of the African Trypanosoma brucei.
    Davitz MA; Gurnett AM; Low MG; Turner MJ; Nussenzweig V
    J Immunol; 1987 Jan; 138(2):520-3. PubMed ID: 2432127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor.
    Brodbeck WG; Liu D; Sperry J; Mold C; Medof ME
    J Immunol; 1996 Apr; 156(7):2528-33. PubMed ID: 8786315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decay-accelerating factor functions as a signal transducing molecule for human monocytes.
    Shibuya K; Abe T; Fujita T
    J Immunol; 1992 Sep; 149(5):1758-62. PubMed ID: 1380538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of decay-accelerating factor (CD55) of the complement system on human spermatozoa.
    Cervoni F; Oglesby TJ; Fénichel P; Dohr G; Rossi B; Atkinson JP; Hsi BL
    J Immunol; 1993 Jul; 151(2):939-48. PubMed ID: 7687624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human complement regulatory proteins expressed on mouse A9 cells containing a human chromosome 1.
    Seya T; Okada M; Hara T; Matsumoto M; Miyagawa S; Oshimura M
    Immunology; 1991 Dec; 74(4):719-24. PubMed ID: 1723716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study of the xenoantigenicity of neonatal porcine islet-like cell clusters (NPCC) and the efficiency of adenovirus-mediated DAF (CD55) expression.
    Omori T; Nishida T; Komoda H; Fumimoto Y; Ito T; Sawa Y; Gao C; Nakatsu S; Shirakura R; Miyagawa S
    Xenotransplantation; 2006 Sep; 13(5):455-64. PubMed ID: 16925670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additional forms of human decay-accelerating factor (DAF).
    Seya T; Farries T; Nickells M; Atkinson JP
    J Immunol; 1987 Aug; 139(4):1260-7. PubMed ID: 2440950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.